- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01434069
Phase I Trial of Combination of FOLFIRI and SOM 230
22 december 2015 uppdaterad av: H. Lee Moffitt Cancer Center and Research Institute
Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI.
We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with standard doses of FOLFIRI.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The goal of this clinical research study is to learn if the study drug SOM 230, also known as Pasireotide long-acting release (LAR), in addition to standard therapy of FOLFIRI (5FU, leucovorin, and irrinotecan) can shrink or slow the growth of gastrointestinal malignancies.
The safety of this drug in combination with standard chemotherapy (FOLFIRI) will also be studied.
The participant's physical state, changes in the size of the tumor, and laboratory findings taken while on-study will help us decide if Pasireotide LAR is safe and effective.
Studietyp
Interventionell
Inskrivning (Faktisk)
16
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Histologically proven metastatic/unresectable gastrointestinal malignancies (colon, small bowel, pancreas, gastric and esophageal cancer, etc.) not amenable to curative surgical therapy, for whom FOLFIRI can be considered a standard treatment
- Have had at least 1 prior treatment for all GI tumors except for small bowel adenocarcinoma as FOLFIRI can be considered standard first line therapy for that particular tumor.
- Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- ≥ 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy (adequately recovered from the acute toxicities of any prior therapy)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, Platelets ≥ 100 x 10^9/L, hemoglobin (Hgb) > 9 g/dL
- Adequate liver function as shown by: serum bilirubin ≤ 2 x upper limit of normal (ULN), and serum transaminases activity ≤ 3 x ULN
- Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN
- Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. Note: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 14 days of the administration of the first study treatment. Women must not be lactating.
- Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information
Exclusion Criteria:
- Prior treatment with irinotecan. Irinotecan with radiation will be allowed if > 4 weeks.
- Any cytotoxic chemotherapy, radiation, immunotherapy, or any investigational drug within the preceding 3 weeks of starting the study treatment
- History of liver disease, such as cirrhosis or chronic active hepatitis B and C
- History of, or current alcohol misuse/abuse within the past 12 months
- Known gallbladder or bile duct disease, ( ie infection or cholecystitis) acute or chronic pancreatitis
- Have undergone major surgery within 4 weeks prior to study enrollment
- Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Patients who have been treated at least 4 weeks prior to enrollment, and have a computed tomography (CT) scan or magnetic resonance imaging (MRI) of brain within 4 weeks of enrollment, which shows no evidence of progression of disease in brain, are allowed to enroll.
- Patients with uncontrolled diabetes mellitus defined as hemoglobin A1c (HbA1c) >8% despite therapy or a fasting plasma glucose > 1.5 ULN. Note: At the principal investigator's discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted.
- Symptomatic cholelithiasis
- Have congestive heart failure: New York Heart Association (NYHA) Class III or IV and unstable angina
- History of syncope or family history of idiopathic sudden death
- Sustained or clinically significant cardiac arrhythmias including sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block (Mobitz II or higher atrioventricular nodal block AV)) , patients with prolonged corrected QT interval (QTc) (longer than 470 milliseconds) or a history of acute myocardial infarction within the 6 months preceding enrollment. (The "QT interval" is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. The "QTc" is the QT interval corrected for heart rate.)
- Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
- Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes or Parkinson's disease), human immunodeficiency virus (HIV), cirrhosis, uncontrolled hypothyroidism or cardiac failure
- Patients found to have sustained ventricular tachycardia, ventricular fibrillation, advanced heart block (Mobitz II or higher AV nodal block) , prolonged QTc (average longer than 470 milliseconds) in the holter monitor at the screening time. (this only applies to patients in cohorts of 60 mg of SOM 230 or higher)
- Concomitant medication(s) known to prolong the QT interval (patient must be off the drug for 2 weeks to be eligible)
- Presence of active or suspected acute or chronic uncontrolled infection or with a history of immunocompromise, including a positive HIV test result
- Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Severely impaired lung function; Any active (acute or chronic) or uncontrolled infection/ disorders; Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy
- Known or suspected allergy or hypersensitivity to any component of FOLFIRI, somatostatin analogues or any component of the pasireotide or octreotide long acting release (LAR) formulations
- No active malignancy except for nonmelanoma skin cancer or in situ cervical cancer or treated cancer from which the patient has been continuously disease free more than 5 years
- Women pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control. WOCBP must have a negative serum pregnancy test within 14 days prior to administration of pasireotide. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study
- Unwilling to or unable to comply with the protocol
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Combination Therapy: FOLFIRI and SOM 230
Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days. |
Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
Andra namn:
Standard therapy of FOLFIRI
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Maximum Tolerated Dose (MTD)
Tidsram: Average of 6 Months Per Participant
|
To determine the maximum tolerated dose (using a standard 3+3 design), of SOM 230 and FOLFIRI.
|
Average of 6 Months Per Participant
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Adverse Events (AEs)
Tidsram: Average of 6 Months Per Participant
|
Evaluate the frequency of toxicities by type and severity, and dose of study drug according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.
|
Average of 6 Months Per Participant
|
Number of Participants With Tumor Response
Tidsram: Average of 6 Months Per Participant
|
Evaluate the frequency of tumor response by dose cohort according to the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.
|
Average of 6 Months Per Participant
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 september 2011
Primärt slutförande (Faktisk)
1 december 2015
Avslutad studie (Faktisk)
1 december 2015
Studieregistreringsdatum
Först inskickad
13 september 2011
Först inskickad som uppfyllde QC-kriterierna
13 september 2011
Första postat (Uppskatta)
14 september 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
24 december 2015
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 december 2015
Senast verifierad
1 december 2015
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Gastrointestinala sjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Skyddsmedel
- Mikronäringsämnen
- Vitaminer
- Motgift
- Vitamin B-komplex
- Fluorouracil
- Leucovorin
- Pasireotid
Andra studie-ID-nummer
- MCC-16569
- SOM230CUS17T (Annan identifierare: Novartis)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Gastrointestinal tumör
-
Henry Ford Health SystemRekryteringBasilar tum artritFörenta staterna
-
AstraZenecaJohnson & Johnson K.K. Medical CompanyAvslutadGastrointestinal endoskopi | Gastrointestinal polypektomiJapan
-
University of AarhusMotilis,SwitzerlandAvslutadMagtömning | Gastrointestinal motilitet | Total gastrointestinal transittid | Segmentell transittidDanmark
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIIRekryteringGastrointestinal motilitetsstörningSpanien
-
The Gut Microbiome Center (Centar za crijevni mikrobiom)University of ZagrebAvslutadGastrointestinal mikrobiomKroatien
-
Coconut Goodness Food Products Inc.Aktiv, inte rekryterandeGastrointestinal dysfunktionFörenta staterna
-
University of GlasgowAktiv, inte rekryterandeGastrointestinal mikrobiomStorbritannien
-
Nutricia ResearchAvslutad
-
James J. Peters Veterans Affairs Medical CenterIndragenGastrointestinal dysfunktionFörenta staterna
-
Cedars-Sinai Medical CenterUniversity of Michigan; NestléAvslutad
Kliniska prövningar på SOM230C LAR
-
Patrick Y. Wen, MDMemorial Sloan Kettering Cancer Center; Massachusetts General Hospital; Northwestern... och andra samarbetspartnersAvslutad
-
Lynn FeunAvslutadHepatocellulärt karcinomFörenta staterna
-
Federico II UniversityUniversity of Genova; University Hospital, Udine, Italy; University of Perugia...AvslutadGastrointestinala neoplasmer | Neoplasmer i andningsvägarna | Pankreatiska neoplasmer | Multipel endokrin neoplasi | Thymiska neoplasmerItalien
-
Azidus BrasilUpphängd
-
Novartis PharmaceuticalsAvslutadCushings sjukdomItalien, Belgien, Japan, Tyskland, Storbritannien, Thailand, Spanien, Frankrike, Nederländerna, Kalkon, Israel, Kina, Förenta staterna, Kanada, Indien, Argentina, Brasilien, Peru, Polen, Ryska Federationen
-
Columbia UniversityAvslutadHypofystumör | ACTH-producerande hypofystumörFörenta staterna
-
PfizerAvslutadAkromegaliKanada, Förenta staterna, Tyskland, Italien, Storbritannien, Norge, Australien, Spanien, Brasilien, Mexiko, Frankrike, Nederländerna
-
Novartis PharmaceuticalsAvslutadKemoterapi-inducerad diarréBrasilien
-
Cedars-Sinai Medical CenterNovartis PharmaceuticalsAvslutad
-
First Affiliated Hospital of Zhejiang UniversityOkänd